virtual service |
||||
|
News for 14-Dec-25 Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet High Blood Pressure General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet Diabetes General Source: MedicineNet High Blood Pressure General |
The Best virtual service websiteAll the virtual service information you need to know about is right
here. Presented and researched by http://www.mdnewscast.net. We've searched
the information super highway far and wide to provide you with the
best virtual service site on the internet today. The links below will
assist you in your efforts to find the information that you are looking
for about
virtual service
At Last - Useful Information on virtual service.Can you imagine the freedom you now have to get to the core of the virtual service information you have been seeking? From the ordeals of working through dozens of virtual service pages to just the right one? What if you could get virtual service links that actually meet your needs?. You'd click on them just like we want you to do now on the one below. If this virtual service link works for you then you do not have to go elsewhere. This virtual service site is just what you're looking for. It's right up there with the best Net information on virtual service. The benefits of have got here are numerous. Your virtual service is over and your virtual service shopping can now begin. Make sure you bookmark this site on virtual service. This virtual service represents a good foot in the door. Don't forget that you probably have many friends who are also interested in virtual service. Make sure they get this URL. Many virtual service websites are open 24 hours a day. If the virtual service site you have now visited has good technology then it will always be available. virtual service sites like this have sound engineering which is an important and vital quality in the hi-tech world of internet commerce. virtual service
Do the best virtual service numbers add up?We assume that your interest in best virtual service has brought you to this site. We also assume that you are shopping for best virtual service online because you'll be able to buy product at a cheaper rate than via a Department Store. Your assumptions are correct so please closely examine the link below. One way to determine if the numbers add up is to check the prices of best virtual service at your local store. Let's assume that you live in New Zealand and are accustomed to buying best virtual service locally. You may find that United States prices are quite amazing even after the normal currency conversions. You've now entered the world of International best virtual service E-Commerce. Just a word of caution. Although the prices for best virtual service internationally may be better than say New Zealand you should also check out the freight and shipping charges. What's the point of getting cheap best virtual service prices which are then converted to very expensive best virtual service prices when the freight is added. Do the numbers add up when freight is taken into account? Our research on many products, including best virtual service, has revealed that many suppliers are now offering best virtual service freight free. This will change the numbers in your favour. The only way for you to fully determine the price elements on offer is to click on the links for the best virtual service merchants which are clearly shown on this page. Our links will take you straight to their website where you will be able to add up the numbers on their online best virtual service products with those in normal best virtual service shops. We definitely think the numbers will stack up in your favour. Class of Drugs Brings Hope to Cancer Patients by: ARA Content
(ARA) - This is an exciting time in cancer research. Recent information on angiogenesis -- the growth of new blood vessels -- is providing researchers opportunities to find new ways to slow or stop a tumor's growth by cutting off the blood supply it needs. Angiogenesis performs a critical role in the development of cancer. To grow, solid tumors need oxygen and nutrients provided by new blood vessels. Once a vascular network has been generated, cancer cells can also invade the rest of the body, a process called metastasis. Currently, researchers believe that more than 90 percent of all cancer cases are angiogenesis-dependent. The good news is that a novel class of drugs, which acts as angiogenesis inhibitors, shows great potential in fighting more than 20 different diseases, including many types of cancer. These "anti-angiogenesis" drugs being developed and tested block the formation of new blood vessels, starving cancerous cells and stopping tumor growth. One drug being tested, Neovastat, was discovered in 1994 and is derived from cartilage tissue. Neovastat is the only angiogenesis inhibitor being developed in the biotechnology and pharmaceutical universe that has four mechanisms of action to combat blood vessel growth. Furthermore, Neovastat is taken orally, making it convenient for patients who need long-term treatment, and it has shown minimal side effects in clinical trials. This means that unlike standard chemotherapy, Neovastat is not likely to interfere with a patient's immune system, or cause adverse gastrointestinal symptoms or hair loss. In addition, because most cancer cells are genetically unstable and more prone to mutations, resistance is a major problem with many chemotherapy agents. But since anti-angiogenesis drugs target normal endothelial cells that are not genetically unstable, drug resistance is less likely to develop and has not been a problem so far in clinical trials. Another hope is that angiogenesis inhibitors can be used in combination with therapies that directly target tumor cells. Because anti-angiogenic drugs and chemotherapy are aimed at different cellular targets, it is possible that the combination will prove even more effective than either therapy is as a stand-alone. Currently, Neovastat is the subject of three clinical trials, targeting three forms of cancer for which there are urgent needs for new therapies. For multiple myeloma, the second most common form of blood cancer, the drug is in phase two trials with 125 patients in the United States, Canada and Europe. This trial should be completed by the end of 2002. For progressive renal cell carcinoma, the drug is in phase three trials with 280 patients in the United States, Canada and Europe, which should be completed in early 2003. For non-small cell lung cancer, Neovastat is in a phase three trial sponsored by the National Cancer Institute with 760 patients in the United States and Canada. This trial should be completed in 2005. Once the clinical trials are complete, health authorities in various countries can then assess test results and make decisions on approval. Neovastat is being developed by Aeterna Laboratories of Quebec, Canada. For more information about current trials, call (888) 349-3232. If you are an oncologist, contact Claude Hariton, PhD, vice president of Clinical and Regulatory Affairs, (418) 652-8525, Ext. 306. To learn more about anti-angiogenesis and Aeterna Laboratories, visit the Aeterna Web site at www.aeterna.com. For more information about the NCI's clinical trials, visit http://cancertrials.nci.nih.gov.
|
|||
|
http://www.medmeet.com/ |
||||
| MD News MD Meet Take Your Meds |